HALO logo

Halozyme Therapeutics (HALO) Current Assets

Annual Current Assets

$1.09 B
+$338.92 M+45.41%

December 31, 2024

Summary

Performance

1-Year Change

+45.41%

3-Year Change

+17.17%

5-Year Change

+99.72%

15-Year Change

+112.66%

HALO Current Assets Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

88.95%
HALO annual total current assets is higher than 88.95% of companies in Healthcare sector

High & Low

All-time High

$1.09 B
HALO annual total current assets is currently at an all-time high

3-Year Low

$739.01 M
HALO annual total current assets is currently +46.86% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
HALO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
HALO next annual earnings announcement has not yet been scheduled

OtherHALObalance sheetmetrics:

Annual Total Assets

$2.06 B
HALO annual total assets is $2.06 billion

Annual Total Liabilities

$1.70 B
HALO annual total liabilities is $1.70 billion

Annual Current Liabilities

$139.10 M
HALO annual total current liabilities is $139.10 million

Annual Total Long Term Liabilities

$1.56 B
HALO annual total long term liabilities is $1.56 billion

Quarterly Current Assets

$1.09 B
-$41.64 M-3.69%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+45.41%

3-Year Change

+23.47%

5-Year Change

+23.47%

HALO Quarterly Current Assets Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89.44%
HALO quarterly total current assets is higher than 89.44% of companies in Healthcare sector

High & Low

All-time High

$1.13 B
HALO quarterly total current assets is currently -3.69% below its historical high of $1.13 billion

3-Year Low

$541.94 M
HALO quarterly total current assets is currently +100.27% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALObalance sheetmetrics:

Quarterly Total Assets

$2.06 B
HALO quarterly total assets is $2.06 billion

Quarterly Total Liabilities

$1.70 B
HALO quarterly total liabilities is $1.70 billion

Quarterly Current Liabilities

$139.10 M
HALO quarterly total current liabilities is $139.10 million

Quarterly Long Term Liabilities

$1.56 B
HALO quarterly total long term liabilities is $1.56 billion

Current Assets Formula

Current Assets = Cash and Equivalents + Accounts Receivable + Inventory + Prepaid Expenses + Marketable Securities + Other Current Assets

Annual Current Assets

$1.09 B
HALO annual total current assets is $1.09 billion

Annual Cash & Cash Equivalents

$115.85 M
HALO annual cash & cash equivalents is $115.85 million

Annual Accounts Receivable

$296.94 M
HALO annual accounts receivable is $296.94 million

Annual Inventory

$141.86 M
HALO annual inventory is $141.86 million

HALO Current Assets Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+45.4%+45.4%
3 y3 years+17.2%+23.5%
5 y5 years+99.7%+23.5%

HALO Current Assets Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+46.9%-3.7%+100.3%
5 y5-yearat high+99.7%-3.7%+131.9%
alltimeall timeat high>+9999.0%-3.7%>+9999.0%

Halozyme Therapeutics Current Assets History

DateAnnualQuarterly
Dec 2024
$978.14 M(-0.9%)
$1.09 B(-3.7%)
Sep 2024
-
$1.13 B(+14.1%)
Jun 2024
-
$987.80 M(+13.1%)
Mar 2024
-
$873.58 M(+17.0%)
Dec 2023
$986.85 M(-10.5%)
$746.42 M(-15.1%)
Sep 2023
-
$879.01 M(+14.8%)
Jun 2023
-
$765.75 M(+24.5%)
Mar 2023
-
$615.02 M(-16.8%)
Dec 2022
$1.10 B(+518.9%)
$739.01 M(+13.1%)
Sep 2022
-
$653.20 M(+20.5%)
Jun 2022
-
$541.94 M(-45.2%)
Mar 2022
-
$988.69 M(+6.7%)
Dec 2021
$178.14 M(+608.0%)
$926.29 M(-8.9%)
Sep 2021
-
$1.02 B(+1.8%)
Jun 2021
-
$999.75 M(+6.2%)
Mar 2021
-
$941.72 M(+69.8%)
Dec 2020
$25.16 M(+12.1%)
$554.76 M(+11.2%)
Sep 2020
-
$498.89 M(-0.3%)
Jun 2020
-
$500.36 M(+6.9%)
Mar 2020
-
$467.97 M(-13.9%)
Dec 2019
$22.44 M(+81.0%)
$543.44 M(+58.9%)
Sep 2019
-
$342.04 M(-12.7%)
Jun 2019
-
$391.71 M(-4.2%)
Mar 2019
-
$409.04 M(-4.4%)
Dec 2018
$12.40 M(+29.5%)
$427.85 M(-0.5%)
Sep 2018
-
$429.93 M(-6.9%)
Jun 2018
-
$462.03 M(-4.6%)
Mar 2018
-
$484.47 M(-5.1%)
Dec 2017
$9.57 M(+92.1%)
$510.37 M(+44.4%)
Sep 2017
-
$353.35 M(+3.7%)
Jun 2017
-
$340.83 M(+53.3%)
Mar 2017
-
$222.35 M(-13.3%)
Dec 2016
$4.98 M(-50.3%)
$256.53 M(-5.9%)
Sep 2016
-
$272.61 M(-4.1%)
Jun 2016
-
$284.34 M(-4.3%)
Mar 2016
-
$297.04 M(+72.9%)
Dec 2015
$10.02 M(+115.1%)
$171.77 M(+12.2%)
Sep 2015
-
$153.09 M(-9.1%)
Jun 2015
-
$168.44 M(+9.9%)
Mar 2015
-
$153.33 M(-5.0%)
Dec 2014
$4.66 M(-29.4%)
$161.32 M(+1.7%)
Sep 2014
-
$158.60 M(-9.7%)
Jun 2014
-
$175.62 M(-8.0%)
Mar 2014
-
$190.91 M(+100.6%)
Dec 2013
$6.60 M
$95.19 M(-7.4%)
Sep 2013
-
$102.82 M(+2.4%)
DateAnnualQuarterly
Jun 2013
-
$100.42 M(-9.6%)
Mar 2013
-
$111.11 M(-14.9%)
Dec 2012
$4.10 M(+131.5%)
$130.63 M(+23.7%)
Sep 2012
-
$105.62 M(-11.8%)
Jun 2012
-
$119.73 M(-9.7%)
Mar 2012
-
$132.57 M(+107.2%)
Dec 2011
$1.77 M(-4.1%)
$63.99 M(-16.9%)
Sep 2011
-
$76.97 M(-12.5%)
Jun 2011
-
$88.01 M(+11.1%)
Mar 2011
-
$79.19 M(-11.5%)
Dec 2010
$1.85 M(-31.8%)
$89.50 M(-9.1%)
Sep 2010
-
$98.43 M(+99.6%)
Jun 2010
-
$49.32 M(-21.3%)
Mar 2010
-
$62.68 M(-15.8%)
Dec 2009
$2.71 M(+6.2%)
$74.44 M(-10.7%)
Sep 2009
-
$83.41 M(-10.9%)
Jun 2009
-
$93.65 M(+41.5%)
Mar 2009
-
$66.18 M(-10.6%)
Dec 2008
$2.55 M(+11.7%)
$74.01 M(-5.4%)
Sep 2008
-
$78.23 M(-9.2%)
Jun 2008
-
$86.12 M(-10.9%)
Mar 2008
-
$96.62 M(-4.5%)
Dec 2007
$2.28 M(+358.7%)
$101.18 M(-6.4%)
Sep 2007
-
$108.08 M(+5.0%)
Jun 2007
-
$102.94 M(+40.5%)
Mar 2007
-
$73.29 M(+60.8%)
Dec 2006
$497.80 K(+23.2%)
$45.59 M(+163.1%)
Sep 2006
-
$17.33 M(+5.3%)
Jun 2006
-
$16.45 M(-11.5%)
Mar 2006
-
$18.58 M(-7.6%)
Dec 2005
$404.10 K(+56.6%)
$20.11 M(+189.8%)
Sep 2005
-
$6.94 M(-34.2%)
Jun 2005
-
$10.55 M(-22.1%)
Mar 2005
-
$13.54 M(-16.1%)
Dec 2004
$258.00 K(>+9900.0%)
$16.15 M(+347.2%)
Sep 2004
-
$3.61 M(-40.1%)
Jun 2004
-
$6.03 M(-20.4%)
Mar 2004
-
$7.57 M(+1402.9%)
Dec 2003
-
$503.60 K(+666.5%)
Sep 2003
-
$65.70 K(-9.5%)
Jun 2003
-
$72.60 K(-21.1%)
Mar 2003
-
$92.00 K(-17.7%)
Sep 2002
-
$111.80 K(-8.7%)
Jun 2002
-
$122.50 K(+223.2%)
Mar 2002
-
$37.90 K
Dec 2001
$0.00
-

FAQ

  • What is Halozyme Therapeutics annual total current assets?
  • What is the all time high annual current assets for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual current assets year-on-year change?
  • What is Halozyme Therapeutics quarterly total current assets?
  • What is the all time high quarterly current assets for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly current assets year-on-year change?

What is Halozyme Therapeutics annual total current assets?

The current annual current assets of HALO is $1.09 B

What is the all time high annual current assets for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual total current assets is $1.09 B

What is Halozyme Therapeutics annual current assets year-on-year change?

Over the past year, HALO annual total current assets has changed by +$338.92 M (+45.41%)

What is Halozyme Therapeutics quarterly total current assets?

The current quarterly current assets of HALO is $1.09 B

What is the all time high quarterly current assets for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly total current assets is $1.13 B

What is Halozyme Therapeutics quarterly current assets year-on-year change?

Over the past year, HALO quarterly total current assets has changed by +$338.92 M (+45.41%)